Assessment of nutritional status in cancer - the relationship between body composition and pharmacokinetics

Anti-Cancer Agents in Medicinal Chemistry

Volumn 13, Issue 8, 2013, Pages 1197-1203

  Prado, Carla M M ^a   Maia, Yara L M ^b   Ormsbee, Michael ^a   Sawyer, Michael B ^c   Baracos, Vickie E ^c  

^a FLORIDA STATE UNIVERSITY   (United States)

^b PAULISTA UNIVERSITY   (Brazil)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Body composition; Cancer; Cancer prognosis; Chemotherapy treatment; Nutritional assessment; Nutritional status; Pharmacokinetics

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CAPECITABINE; EPIRUBICIN; SORAFENIB;

ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY COMPOSITION; BODY MASS; BODY WEIGHT; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOTOXICITY; ENERGY EXPENDITURE; FUNCTIONAL STATUS; HORMONAL REGULATION; HUMAN; INCIDENCE; KIDNEY CANCER; LIVER CELL CARCINOMA; NEOPLASM; NUTRIENT UPTAKE; NUTRITIONAL ASSESSMENT; NUTRITIONAL STATUS; PREVALENCE; QUALITY OF LIFE; QUESTIONNAIRE; SARCOPENIA; TUMOR GROWTH; WEIGHT REDUCTION;

ANTINEOPLASTIC AGENTS; BODY COMPOSITION; BODY MASS INDEX; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; NEOPLASMS; NIACINAMIDE; NUTRITIONAL STATUS; NUTRITIONAL SUPPORT; PHENYLUREA COMPOUNDS;

EID: 84888215692     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/18715206113139990322     Document Type: Article

References (44)

1. Gibson, R.S. Principles of Nutritional Assessment; Oxford University Press: New York, 1990.
2. Baracos VE. Cancer-associated cachexia and underlying biological mechanisms. Ann. Rev. Nutr., 2006, 26, 435-461.
3. Dewys, W.D.; Begg, C.; Lavin, P.T.; Band, P.R.; Bennett, J.M.; Bertino, J.R.; Cohen, M.H.; Douglass, H.O. Jr., Engstrom, P.F.; Ezdinli, E.Z.; Horton, J.; Johnson, G.J.; Moertel, C.G.; Oken, M.M.; Perlia, C.; Rosenbaum, C.; Silverstein, M.N.; Skeel, R.T.; Sponzo, R.W.; Tormey, D.C. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am. J. Med., 1980, 69(4), 491-497.
4. Fearon, K.; Strasser, F.; Anker, S.D.; Bosaeus, I.; Bruera, E.; Fainsinger, R.L.; Jatoi, A.; Loprinzi, C.; MacDonald, N.; Mantovani, G.; Davis, M.; Muscaritoli, M.; Ottery, F.; Radbruch, L.; Ravasco, P.; Walsh, D.; Wilcock, A.; Kaasa, S.; Baracos, V.E. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol., 2011, 12(5), 489-495.
5. Baracos, V.; Prado, C.M.; Antoun, S.; Gioulbasanis, I. Assessement of nutritional status; Del Fabbro E, Baracos, V.; Demark- Wahnefried, W.; Bowling, T, J. H, Bruera E, Eds.; Nutrition and the Cancer Patient, 2010; Oxford University Press:Oxford, pp.19-36.
6. Buzby, G.P.; Mullen, J.L.; Matthews, D.C.; Hobbs, C.L.; Rosato, E.F. Prognostic nutritional index in gastrointestinal surgery. Am. J. Surg., 1980, 139(1), 160-167.
7. Ingenbleek, Y.; Carpentier, Y.A. A prognostic inflammatory and nutritional index scoring critically ill patients. Int. J. Vitam. Nutr. Res., 1985, 55(1), 91-101.
8. Vehe, K.L.; Brown, R.O.; Kuhl, D.A.; Boucher, B.A.; Luther, R.W.; Kudsk, K.A. The prognostic inflammatory and nutritional index in traumatized patients receiving enteral nutrition support. J. Am. Coll. Nutr., 1991, 10(4), 355-363.
9. Walsh, D.; Mahmoud, F.; Barna, B. Assessment of nutritional status and prognosis in advanced cancer: interleukin-6, C-reactive protein, and the prognostic and inflammatory nutritional index. Support Care Cancer, 2003, 11(1), 60-62.
10. Chen, Z. Body composition and cancer. Heymsfield, S.B.; Lohman, T.; Wang, Z.; Going, S.; Eds.; Human body composition. Human Kinetics: Champaign, 2005, pp. 351-364.
11. Harvie, M.N.; Campbell, I.T.; Thatcher, N.; Baildam, A. Changes in body composition in men and women with advanced nonsmall cell lung cancer (NSCLC) undergoing chemotherapy. J. Hum. Nutr. Diet., 2003, 16(5), 323-326.
12. Fearon, K.C.; Von Meyenfeldt, M.F.; Moses, A.G.; Van Geenen, R.; Roy, A.; Gouma, D.J.; Giacosa, A.; Van Gossum, A.; Bauer, J.; Barber, M.D.; Aaronson, N.K.; Voss, A.C.; Tisdale, M.J. Effect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomised double blind trial. Gut, 2003, 52(10), 1479-1486.
13. Fouladiun, M.; Korner, U.; Bosaeus, I.; Daneryd, P.; Hyltander, A.; Lundholm, K.G. Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care--correlations with food intake, metabolism, exercise capacity, and hormones. Cancer, 2005, 103(10), 2189-2198.
14. Prado, C.M.M.; Mourtzakis, M.; Baracos, V.; Reiman, T.; Sawyer, M.; McCargar, L.J. Overweight and obese patients with solid tumors may have sarcopenia, poor prognosis and early features of cachexia. Int. J. Body Comp. Res., 2010, 8(1), 7-15.
15. Prado, C.M.; Lieffers, J.R.; McCargar, L.J.; Reiman, T.; Sawyer, M.B.; Martin, L.; Baracos, V.E. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol., 2008, 9(7), 629-635.
16. Prado, C.M.; Birdsell, L.A.; Baracos, V.E. The emerging role of computerized tomography in assessing cancer cachexia. Curr. Opin. Support. Palliat Care, 2009, 3(4), 269-275.
17. Mourtzakis, M.; Prado, C.M.M.; Lieffers, J.R.; Reiman, T.; McCargar, L.J.; Baracos, V.E. A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl. Physiol. Nutr. Metab., 2008, 33(5), 997-1006.
18. MacDonald, A.J.; Greig, C.A.; Baracos, V. The advantages and limitations of cross-sectional body composition analysis. Curr. Opin. Support Palliat. Care, 2011, 5(4), 342-349.
19. Cohn, S.H.; Gartenhaus, W.; Sawitsky, A.; Rai, K.; Zanzi, I.; Vaswani, A.; Ellis, K.J.; Yasumura, S.; Cortes, E.; Vartsky, D. Compartmental body composition of cancer patients by measurement of total body nitrogen, potassium, and water. Metabolism, 1981, 30(3), 222-229.
20. Pichard, C.; Baracos, V.; Attaix, D. Would you buy a new tool to improve your practice? Curr. Opin. Clin. Nutr. Metab. Care, 2011, 14(3), 221-222.
21. Miyake, K.; Hayakawa, K.; Nishino, M.; Morimoto, T.; Mukaihara, S. Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer. Acad. Radiol., 2005, 12(6), 722-727.
22. Prado, C.M.; Baracos, V.E.; McCargar, L.J.; Reiman, T.; Mourtzakis, M.; Tonkin, K.; Mackey, J.R.; Koski, S.; Pituskin, E.; Sawyer, M.B. Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin. Cancer Res., 2009, 15(8), 2920-2926.
23. Antoun, S.; Baracos, V.E.; Birdsell, L.; Escudier, B.; Sawyer, M.B. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann. Oncol., 2010, 21(8), 1594-1598.
24. Tan, B.H.; Birdsell, L.A.; Martin, L.; Baracos, V.E.; Fearon, KC. Sarcopenia in an overweight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin. Cancer Res., 2009, 15(22), 6973-6979.
25. Baracos, V.E.; Reiman, T.; Mourtzakis, M.; Gioulbasanis, I.; Antoun, S. Body composition in patients with non-small cell lung cancer: A contemporary view of cancer cachexia with the use of computed tomography image analysis. Am. J. Clin. Nutr., 2010, 91(4), 1133S-1137S.
26. Parsons, H.A.; Baracos, V.E.; Dhillon, N.; Hong, D.S.; Kurzrock, R. Body composition, symptoms, and survival in advanced cancer patients referred to a phase I service. PLoS One, 2012, 7(1), e29330.
27. Roubenoff, R. Sarcopenic obesity: The confluence of two epidemics. Obes Res, 2004, 12(6), 887-888.
28. Roubenoff, R. Excess baggage: Sarcopenia, obesity, and cancer outcomes. Lancet Oncol., 2008, 9(7), 605-607.
29. Aslani, A.; Smith, R.C.; Allen, B.J.; Levi, J.A. Changes in body composition during adjuvant chemotherapy for breast cancer. Appl. Radiat. Isot., 1998, 49(5-6), 637-638.
30. Mosteller, R.D. Simplified calculation of body-surface area. N. Engl. J. Med., 1987, 317(17), 1098.
31. Sawyer, M.; Ratain, M.J. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest. New Drugs, 2001, 19(2), 171-177.
32. Ratain, M.J. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J. Clin. Oncol., 1998, 16(7), 2297-2298.
33. Prado, C.M.; Baracos, V.E.; McCargar, L.J.; Mourtzakis, M.; Mulder, K.E.; Reiman, T.; Butts, C.A.; Scarfe, A.G.; Sawyer, M.B. Body composition as an independent determinant of 5-fluorouracil- based chemotherapy toxicity. Clin. Cancer Res., 2007, 13(11), 3264-3268.
34. Aslani, A.; Smith, R.C.; Allen, B.J.; Pavlakis, N.; Levi, J.A. The predictive value of body protein for chemotherapy-induced toxicity. Cancer, 2000, 88(4), 796-803.
35. Gurney, H. How to calculate the dose of chemotherapy. Br. J. Cancer, 2002, 86(8), 1297-1302.
36. Morgan, D.J.; Bray, K.M. Lean body mass as a predictor of drug dosage. Implications for drug therapy. Clin. Pharmacokinet., 1994, 26(4), 292-307.
37. Roubenoff, R.; Kehayias, J.J. The meaning and measurement of lean body mass. Nutr. Rev., 1991, 49(6), 163-175.
38. Lieffers, J.R.; Bathe, O.F.; Fassbender, K.; Winget, M.; Baracos, V.E. Sarcopenia is associated with postoperative infection and delayed recovery from colorectal cancer resection surgery. Br. J. Cancer, 2012, 107(6), 931-936.
39. Baker, S.D.; Grochow, L.B.; Donehower, R.C. Should anticancer drug doses be adjusted in the obese patient? J. Natl. Cancer Inst., 1995, 87(5), 333-334.
40. Gusella, M.; Toso, S.; Ferrazzi, E.; Ferrari, M.; Padrini, R. Relationships between body composition parameters and fluorouracil pharmacokinetics. Br. J. Clin. Pharmacol., 2002, 54(2), 131-139.
41. Parsons, H.A.; Tsimberidou, A.M.; Pontikos, M.; Fu, S.; Hong, D.; Wen, S.; Baracos, V.E.; Kurzrock, R. Evaluation of the clinical relevance of body composition parameters in patients with cancer metastatic to the liver treated with hepatic arterial infusion chemotherapy. Nutr. Cancer, 2012, 64(2), 206-217.
42. Cosolo, W.C.; Morgan, D.J.; Seeman, E.; Zimet, A.S.; McKendrick, J.J.; Zalcberg, J.R. Lean body mass, body surface area and epirubicin kinetics. Anticancer Drugs, 1994, 5(3), 293-297.
43. Prado, C.M.; Lima, I.S.; Baracos, V.E.; Bies, R.R.; McCargar, L.J.; Reiman, T.; Mackey, J.R.; Kuzma, M.; Damaraju, V.L.; Sawyer, M.B. An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity. Cancer Chemother. Pharmacol., 2011, 67(1), 93-101.
44. Mir, O.; Coriat, R.; Blanchet, B.; Durand, J.P.; Boudou-Rouquette, P.; Michels, J.; Ropert, S.; Vidal, M.; Pol, S.; Chaussade, S.; Goldwasser, F. Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One, 2012, 7(5), e37563.